Targeted Therapy [topp]    
Advance [qlco]    
Gall Bladder Cancer [neop]    
Cholangiocarcinoma [neop]    
Aggression [mobd]    
Biology [bmod]    
elicit [qlco]    
Early [tmco]    
Response [orga]    
Signal [phpr]    
Phase 1 [tmco]    
Trial [resa]    
Purpose [ftcn]    
patient [podg]    
Advance [qlco]    
Cholangiocarcinoma [neop]    
Gallbladder Carcinoma [neop]    
Few [qnco]    
Therapeutic [topp]    
Option [ftcn]    
DISEASE RELAPSE [dsyn]    
Method [inpr]    
GIVEN [cnce]    
Overall [inpr]    
Poor prognosis [fndg]    
Population [qnco]    
Availability [ftcn]    
Novel [tmco]    
Targeted Therapy [topp]    
Analyzed [resa]    
Characteristic [qlco]    
Outcome [ftcn]    
Gallbladder Carcinoma [neop]    
Cholangiocarcinoma [neop]    
patient [podg]    
TREAT [topp]    
Phase I Trial [resa]    
Target [ftcn]    
Agent [chvf]    
Therapies [topp]    
Result [ftcn]    
/40 [tmco]    
TREAT [topp]    
patient [podg]    
Gallbladder Carcinoma [neop]    
Cholangiocarcinoma [neop]    
median [spco]    
Age [orga]    
year [tmco]    
Stable Disease [fndg]    
month [tmco]    
<3 [qnco]    
partial response [fndg]    
Protocol [inpr]    
hepatic arterial infusion [topp]    
Drug [phsu]    
Angiogenic [ortf]    
HER-2/NEU [gngm]    
Novel [tmco]    
MAPK/ERK Kinase Inhibitor [phsu]    
median [spco]    
Progression-Free Survival [qnco]    
Phase I Trial [resa]    
2 Months [tmco]    
+2 [qnco]    
3 Months [tmco]    
>5 [qnco]    
3 Months [tmco]    
3 Months [tmco]    
3/9 [fndg]    
First [qnco]    
Second [qnco]    
Last [qlco]    
Line [spco]    
FDA [hcro]    
Approval [qlco]    
Therapies [ftcn]    
univariate analysis [resa]    
<3 [qnco]    
Metastatic [ftcn]    
Site [spco]    
elevate [qlco]    
Serum creatinine [lbpr]    
1+ [qnco]    
/dL [qnco]    
/mL [qnco]    
Associated [qlco]    
short [qlco]    
Progression-Free Survival [qnco]    
mutation analysis [lbpr]    
reveal [qlco]    
Mutate [genf]    
K-ras Oncogene [gngm]    
+2 [qnco]    
patient [podg]    
Stable Disease [fndg]    
month [tmco]    
partial response [fndg]    
Rate [acty]    
Seen [qlco]    
hepatic arterial infusion [topp]    
Inhibitor [chvf]    
Angiogenesis [ortf]    
HER-2/NEU [gngm]    
Conclusion [idcn]    
Progression-Free Survival [qnco]    
Phase I Trial [resa]    
Similar [qlco]    
First [qnco]    
Second [qnco]    
Last [qlco]    
Line [spco]    
Therapies [ftcn]    
FDA [hcro]    
Approval [qlco]    
Agent [chvf]    
GIVEN [cnce]    
Advance [qlco]    
Set [ftcn]    
Role [socb]    
Target [ftcn]    
Agent [chvf]    
Clinical Trial [resa]    
Set [ftcn]    
Therapeutic [topp]    
Option [ftcn]    
patient [podg]    
